Arcutis Biotherapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview

Arcutis Biotherapeutics

10/05/2024 22:35

* Arcutis Biotherapeutics Inc  ARQT.OQ   ARQT.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 14 for the period ending March 31 2024
    * The Westlake Village California-based  company is expected
to
report a 427.9% increase in revenue to $14.68 million from $2.78
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Arcutis Biotherapeutics
Inc is
for a loss of 73 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arcutis
Biotherapeutics Inc is $17.50​, above​ its last closing price
of $8.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.75       -0.77      -0.72     Beat    7.1
 Sep. 30 2023  -0.70       -0.86      -0.73     Beat    14.9
 Jan. 1 0001   -1.25       -1.25      -1.16     Beat    7.2​
 Mar. 31 2023  -1.26       -1.28      -1.31     Missed  -2
 ​​Dec.        -1.41       -1.42      -1.18     Beat    17.1
 31 2022                                                
 Sep. 30 2022  -1.70       -1.67      -1.89     Missed  -13.2​
 Jun. 30 2022  -1.41       -1.43      -1.31     Beat    8.6
 Mar. 31 2022  -1.51       -1.50      -1.27     Beat    15.4
 This summary was machine generated May 10 at 21:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)